Drugs Controller General of India (DCGI) on Tuesday gave emergency use approval to US drugmaker Eli Lilly and Co for its antibody drugs combination used for treatment of mild to moderate Coronavirus in the country.
According to a statement issued by the US firm, the DGCI has granted permission for restricted emergency use of its monoclonal antibody drugs – Bamlanivimab 700 mg and Eesevimab 1400 mg, used together for the treatment of patients with mild to moderate COVID-19.
“Lilly is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab in order to speed up access and provide treatment options for patients with COVID-19,” the company said.